Lava Therapeutics NVLVTX
13F holders, Q2 2025 (June 30)19holders −1
3new positions
4sold out
1famous investor
$1.32avg. 13F price*
At the end of Q2 2025, 19 institutions reported holding Lava Therapeutics NV (LVTX) in their 13F filings, down 1 from Q1 2025. 3 opened new positions and 4 sold out. The largest holders were Redmile Group, LLC ($2.7M), BML Capital Management, LLC ($2.6M) and Sanofi ($2.5M). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Lava Therapeutics NV
- CUSIP
- N51517105
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $55K |
| Exits | 4 | $95K |
All 13F filers, Q1 2025 → Q2 2025: 108,090 shares bought and 101,149 shares sold, net +6,941 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Redmile Group, LLC | 0.29% | No change | 2,074,372 | $2.7M |
| BML Capital Management, LLC | 1.99% | Add +0.5% | 1,970,610 | $2.6M |
| Sanofi | 1.44% | No change | 1,919,455 | $2.5M |
| Merck & Co., Inc. | 0.70% | No change | 1,149,345 | $1.5M |
| Bruce & Co., Inc. | 0.22% | No change | 521,874 | $689K |
| Pathway Financial Advisors LLC | 0.02% | No change | 102,500 | $135K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 65,000 | $86K |
| Citadel Advisors | 0.00% | Add +931.3% | 51,804 | $68K |
| BNP Paribas Financial Markets | 0.00% | Add +3.5% | 46,900 | $62K |
| Two Sigma Investments, LP | 0.00% | Reduce -40.4% | 34,412 | $45K |
| Lepercq De Neuflize Asset Management LLC | 0.04% | Add +34.8% | 31,000 | $41K |
| Rangeley Capital, LLC | 0.05% | New | 27,073 | $36K |
| UBS Group AG | 0.00% | Reduce -3.0% | 16,380 | $22K |
| Two Sigma Securities, LLC | 0.00% | New | 14,236 | $19K |
| Geode Capital Management, LLC | 0.00% | Reduce -12.3% | 14,170 | $19K |
| Morgan Stanley | 0.00% | Reduce -1.7% | 11,600 | $15K |
| Tsfg, LLC | 0.00% | No change | 400 | $1K |
| Jones Financial Companies LLLP | 0.00% | New | 400 | $528 |
| SBI Securities Co., Ltd. | 0.00% | No change | 300 | $396 |
"% of holder's portfolio" is LVTX's weight in each manager's 13F, not the share of Lava Therapeutics NV the manager owns.